Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20945159 | 0.91 | TNF (0.45) | PARP1KDM4EALDH1A1ELANEKAT2B | |
| SCHEMBL8649103 | 0.84 | ELANE (0.51) | KDM4EALDH1A1ELANEL3MBTL1NPC1 | |
| SCHEMBL20945122 | 0.84 | ELANE (0.39) | PARP1KDM4EALDH1A1ELANEL3MBTL1 | |
| Hydrochloric Acid SCHEMBL20944983 | 0.83 | ELANE (0.50) | KDM4EALDH1A1ELANEL3MBTL1NPC1 | |
| SCHEMBL16918355 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1KAT2BCNR1CNR2 | |
| SCHEMBL21924444 | 0.81 | ELANE (0.39) | PARP1KDM4EALDH1A1ELANECNR1 | |
| SCHEMBL27901313 | 0.81 | RAB9A (0.50) | KDM4EALDH1A1CNR1CNR2NPC1 | |
| SCHEMBL13075101 | 0.78 | ALDH1A1 (0.41) | PARP1ALDH1A1ELANENPC1RAB9A | |
| SCHEMBL6968546 | 0.77 | ELANE (0.47) | KDM4EALDH1A1ELANEL3MBTL1NPC1 | |
| SCHEMBL20945015 | 0.77 | ELANE (0.44) | PARP1KDM4EALDH1A1ELANEL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| EP-3478671-B1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-05-13 | — | — | EP | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127349-A1 | PYRIDAZINONE-BASED BROAD SPECTRUM ANTI-INFLUENZA INHIBITORS | ABCG2, PIR, PRNP | PARP1 2322/4885KDM4E 1753/4885ALDH1A1 1626/4885 |
| US-10597380-B2 | Pyridazinone-based broad spectrum anti-influenza inhibitors | ABCG2, PIR, PRNP | PARP1 2322/4885KDM4E 1753/4885ALDH1A1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.